Indeed, the intratumoral heterogeneity seen in renal carcinoma led to phenotypic diversity in the form of activating mutations in MTOR, which may predict for intrinsic resistance to drugs targeting the PI3K-MTOR pathway. Here, MTOR is linked to renal carcinoma.